Xilio Therapeutics, the Waltham-based cancer biotech that rebranded from Akrevia Therapeutics back in early 2020, has made its Wall Street debut. The company raised $117.5 million in an IPO on Friday, selling nearly 7.4 million shares at $16 apiece.

Xilio is trading on the Nasdaq under the symbol “XLO.” Midday trading saw shares trading at just over $15 each, a drop of about 5%.

Sign up for the BioFlash e-newsletter, your free twice-weekly source for medical device and life sciences news in…

Boston Biz Journal https://www.bizjournals.com/boston/news/2021/10/22/xilio-therapeutics-akrevia-ipo.html?ana=RSS&s=article_search